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Abstract 
Published ata on growth rates of uveal melanomas and effects of treatment modalities raise important considera- 
tions. Dissemination from uveal melanomas starts after the tumour is larger than 7 mm diameter; growth from 7 
to 10 mm diameter increases the risk of metastases incrementally to approximately 16%. Estimations of turnout 
doubling times indicate that metastatic death before 8 years is nearly always due to pre-therapeutic dissemination 
so that the impact on survival by therapy can only be assessed thereafter. Histopathology onirradiated melanomas 
reveals that reproductive activity has not been suppressed and the anticipated (and unfavourable) risk of metas- 
tases is not balanced by poor post-irradiation visual acuity. Also the psychological well-being of a patient with a 
functional fellow eye is better after primary enucleation. Conservative management is most appropriate for: small 
melanomas, patients with a short life expectancy, melanomas in a single functioning eye, and patients refusing 
enucleation. 
Optimum treatment of any form of neoplastic dis- 
ease by modern therapeutic modalities hould ideally 
be based on an accurate knowledge of the biologi- 
cal behaviour of the specific neoplastic process. With 
regard to ocular melanomas, there are serious gaps in 
knowledge concerning rowth rates in situ and in the 
documentation f the time intervals between the pre- 
sentation of the primary tumour and the appearance 
of metastases. The rarity of the tumour necessitates 
careful accumulation ofdata, so that an adequate anal- 
ysis can be made of the claimed success of cure rates. 
Equally important, the side effects and the compli- 
cations of treatment should be the subject of careful 
scrutiny. In this communication the literature on the 
relevant aspects of melanoma biology and current treat- 
ment modalities i  critically analysed. 
Tumour biology 
Tumour doubling time 
Information on tumour doubling time of uveal 
melanomas was introduced in 1980 [1] and updated 
reviews were provided in 1987 [2] and in 1992 [3]. 
From this data it was possible to estimate the risk of 
metastatic disease in relation to the dimensions of the 
tumour. The application of meta analysis provided by 
Diener-West and associates [4] and Markowitz et al. [5] 
has indicated that a radical reappraisal of the current 
philosophy of management is required. 
When do uveal melanomas metastasize ? 
In 1984, an editorial in the American Journal of Oph- 
thalmology stated that 'it is unclear at what stage in 
its course a uveal melanoma develops the capacity 
to metastasize' [6]. However an analysis of the data 
then available in the literature provided evidence which 
indicated that metastatic disease does not occur until 
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Table 1. Metastatic death after enucleation small melanomas. Davidorf et al. [8]. 
Diameter < I0 mm < 7 mm 7-10 mm 
Number cases 50 18 32 
Number 10 yr follow-up 18 + 3 tumour death ? ? 
Lost to follow-up 29 ? ? 
Tumour-related death 5 (10%) 0 5 (16%) 
the tumour dimensions are greater than a diameter of 
6-7 mm [7]. This conclusion was based on two sepa- 
rate studies of survival from small melanomas treated 
by enucleation [8, 9]. In both series [8, 9], metastatic 
death had not occurred in the < 7 mm diameter groups, 
but had occurred in 10% [8] and 9% [9] in the < 10 
mm diameter groups; it is noteworthy that the < 10 mm 
group also included the < 7 mm cases. Recalculation of 
this data [8, 9] revealed that the percentage metastatic 
death rate in the group tumours measuring 7-10 mm in 
diameter groups appeared to be 16% and 26%, against 
zero in the < 7 mm diameter groups (Tables 1, 2). There 
are exceptions, however: one patient with a melanoma 
< 7 mm had metastases, but had not yet died. In the 
literature thereafter, only one more case of metastat- 
ic death after enucleation i  a patient with a < 7 mm 
melanoma has been reported [10]. This data strongly 
suggests that choroidal melanomas rarely metastasize 
when the tumours have a diameter less than 6-7 mm 
at the time of detection. 
Death rates in patients with melanomas less than 
10 mm diameter 
The previously cited editorial [6] also stated that 
patients with melanomas < 10 mm diameter had 'an 
excellent prognosis regardless of treatment; he five- 
year tumour-related mortality in this group is less than 
5%'. This statement, clearly contradicted by the obser- 
vation shown in Tables 1 and 2, can be seriously chal- 
lenged by the application of meta-analysis, which pro- 
vides proof that five-year mortality rate in patients with 
melanomas < 10 mm diameter is 16% [4]. This implies 
that prolonged clinical observation of melanomas as 
they enlarge from 7 mm diameter to 10 mm diame- 
ter could result in the death of 16% of these patients. 
However it is too simplistic to suggest hat all such 
patients with small pigmented tumours of 6-7 mm or 
less should be treated by immediate nucleation since 
many such tumours could be n~evi and the majority 
of melanomas are not brought o the attention of oph- 
thalmologists atthis stage. Nonetheless on theoretical 
grounds, metastatic death could have been averted by 
complete radication of the malignant neoplasm at the 
6-7 mm stage and this important postulate should not 
be neglected. 
Failure to appreciate the consequences of 'doubling 
time' 
The new approach to uveal melanomas, published in 
1980 [1], with regard to their biological behaviour, was 
based on the published ata on skin melanomas, for 
which tumour doubling times (Td's) had been calculat- 
ed. Information derived from this literature showed that 
the time intervals between dissemination a d metastat- 
ic death were widely spread and varied between 3 and 
30 years. 
Subsequently numerous reports on tumour dou- 
bling times in uveal melanomas have been provided 
[11-14]; in only three out of thirty-nine patients were 
the doubling times estimated tobe shorter than 60 days. 
On theoretical grounds it has been suggested that 
metastatic tumour death (after the primary tumour has 
released cells into the circulation) will occur at a time 
interval derived from multiplication of the tumour dou- 
bling time by 35--40 [15]. This postulate (which does 
not assume that all metastases grow exponentially from 
the first cell division to a clinically detectable size, 
because the tumour doubling time represents a mean 
value) has not been contradicted in later studies [see 
reference 3], which have repeated and extended the 
fundamental work of Collins [ 15]. 
Taking these two assumptions together, it may, 
therefore, be accepted for practical therapeutic and 
prognostic onsiderations in individual patients, that 
death from metastatic death in unlikely to occur before 
35 • 60 days or no less than six years after dissemina- 
tion of the first viable embolus of tumour cells. 
Furthermore, since the turnout doubling times of 
uveal melanomas may exceed 200 days, the time inter- 
val between dissemination and metastatic death may 
vary widely and range from 6 to 60 years. Crowley [16] 
reported a mean disease-free interval for cutaneous 
Table 2. Metastatic death after enucleation small melanomas. Thomas et al. [9]. 
Diameter < 10 mm < 7 mm 7-10 mm 
Number cases 65 42 23 
Number 10 yr follow-up 27 (0 tumour death) ? ? 
Lost to follow-up 38 ? ? 
Tumour-related death 6 (9%) 0 6 (26%) 
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melanomas of 14.3 years and compared this with 22.3 
years for primary ocular lesions. It is noteworthy that 
in this series [16], five out of twelve ocular melanoma 
patients had a tumour-free interval of 47, 45, 30, 28 
and 27 years, respectively. 
The minimal latent interval of six years implies that 
metastatic death within 7-8 years after local therapy 
on the uveal melanoma is nearly always due to pre- 
therapeutic dissemination. This is the only reason why 
a statistically significant impact on survival has never 
been and never will be established by a detailed ana- 
lytical comparison of survival rates within 8-10 years 
after various conservative interventions, after primary 
enucleation or after observation only. It is therefore 
more likely that differences in survival rates after any 
given form of treatment will reflect he selection crite- 
ria for patients ubjected to that specific form of treat- 
ment. The validity of this postulate is supported by the 
agreement in all reports, that within the first 8-10 years 
no significant difference in survival rate has ever been 
noted when various treatment modalities are compared 
[ 17-21 ] or when survival in 'promptly treated patients' 
is compared with those in whom 'treatment has been 
delayed' [22]. 
Therefore, the essential requirements for valid sta- 
tistical comparisons are: 
- a 10-15 year survival rate of all treated patients, and 
- accurate assessment of visual function in all living 
patients after a 5-year or more follow- up, without 
any selection bias. 
Many ophthalmic oncology institutes have employed 
conservative management i  uveal melanomas for 15- 
20 years, but rather surprisingly, results after follow- 
up periods of 10 years or more of all treated patients 
have not been made available. Neglect in providing 
this fundamental information has been highlighted by 
Markowitz et al. [5], who emphasized that researchers, 
clinicians, journal editors, and reviewers hould be 
more attentive to the completeness of reports from 
clinical research studies; attention to basic informa- 
tion regarding design and methods was strongly rec- 
ommended. Statements made by these authors [5] con- 
cerning the overall quality of reporting (which have 
not improved over the last two decades) should not be 
ignored. Publication of unverifiable data still continues 
e.g. visual acuities between 6/24 and zero are unspec- 
ified, and statements such as 'stable disease', defined 
as 'an elevated remnant, remaining unchanged for at 
least one year' are equally vague [23]. 
Tumour biology in relation to ionising radiation 
A consideration of the histopathological findings in 
231 eyes containing irradiated melanomas was provid- 
ed in 1992 [3]. Thereafter, another 170 such patholog- 
ical studies have been reported [24-31]. A substantial 
number of irradiated tumours are treated successfully, 
but the actual percentage ofloss of proliferative capac- 
ity of all stem cells will never be known. To compound 
the difficulty in assessment, a sufficient follow-up eri- 
od for all irradiated patients may never be achieved 
and by the very nature of the treatment, radiothera- 
py is applied to 'masses' which are not histologically 
classified. 
The well-established radio-insensitivity of uveal 
melanomas i reflected in the absence of radiation- 
induced necrosis in about 40% of the treated tumours, 
and in the identification of well-preserved tumour cells 
in about 95% of the specimens [3]. Appearances sug- 
gesting continuing tumour cell activity was noted in 
rutheniuml~ melanomas in 55 of 56 cas- 
es [24]. On the other hand, microscopically com- 
plete tumour necrosis was found in 10 out of 25 
large melanomas, measuring > 7-8 mm in height 
after iodine125-brachytherapy [25]. In another eport 
unequivocal mitoses were found in 36% of tumours, 
treated with various types of radioactive plaques: enu- 
cleation was performed at an average of 29 months after 
therapy [26]. Mitoses were also reported in 20% of 25 
rutheniuml~ melanomas [27]. Mitoses after 
proton beam irradiation have been described in 9 (27%) 
of 33 melanomas [28]. Similar data was obtained from 
five proton beam-treated turnouts in five patients [29] 
and in four of seven cases [30]. The two latter eports 
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Table 3. Reported visual acuities (VA) or adverse visual events (AVE)*. 
No. Follow-up VA or AVE 
Lommatzsch (1986) ~ 33 227 5 years First VA > 0.3:31 (14%) 3
Last VA < 0.2:83 (37%) 3
Tjho-Heslinga (1993) a23 49 1-6 years First VA < 0.25:9 (19%) 
Last VA_< 0.25:19 (39%) 
Linstadt (1988) b34 189 median First VA > 0.1:164 (87%) 
26 months Last VA _> 0.1:89 (48%) 
Kindy-Degnan (1989) b35 279 3 years First VA > 0.5:173 (62%) 
Last VA > 0.5:27 (10%) 
First VA > 0.1:238 (85.3%) 
Last VA > 0.1:35 (12.5%) 
Char (1993) b36 86 4-5 years First VA > 0.5:26 (30%) 
Last VA > 0.5:16 (19%) 
First VA _< 0.1:6 (7%) 
Last VA < 0.1:58 (67.4%) 
Char (1993) c 36 98 4-5 years First VA >_ 0.5:29 (29%) 
Last VA _> 0.5:23 (23.5%) 
First VA _< 0.1:9 (9.2%) 
Last VA < 0.1:66 (67%) 
Packer (1992) c37 63 mean Total AVE: 49 (77.8%) 
65 months Last VA < 0.1:35 (55%) 
Fontanesi (1993) c 38 144 median First VA < 0.1:29% 3 
46 months Last VA < 0.1:59% 3 
Guyer (1992) a39 218 mean First VA < 0.1:22 (10%) 3
40 months Last VA < 0.1:86 (39.4%) 3 
a Ruthenium106; b Helium ions; c iodine125; ,t Proton beam. * Adverse visual event: acuity 
decreased to _< 6/30 or _> 2 lines. 3 Data unverifiable orconcerning selected groups of patients. 
noted intervals between irradiation and enucleation of 
36, 49 and 66 months. Mitoses in a growing tumour and 
mitoses of more than two years after irradiation must 
be regarded as significant indicators of the presence 
of viable tumour stem cells. Their presence indicates a
failure of irradiation to abolish the proliferative capac- 
ity of the stem cells within the tumour. 
Clinical implications 
The importance of long-term visual acuity data 
Preservation of  vision is the principle justification for 
conservative management of ocular melanomas. It is 
unfortunate therefore, that some of the radiotherapeu- 
tic and surgical centres which publish regularly, have 
been reluctant to present verifiable, detailed ata on the 
retained visual acuity of all treated patients. In general, 
fol low-up periods of visual function have been short- 
er than those for other data relevant o the treatment 
and further management of the patients. An extreme 
example of a great potential for bias is presented in 
a report [32] published in 1993, on 163 patients who 
had been treated between 1972 and 1991. This study 
mentions only a 'one-year (!) post-operatively retained 
visual acuity of all patients'. Moreover, vision had been 
measured with a pinhole aperture. The reported visual 
acuity is, therefore, in no sense representative of the 
post-therapeutic quality of life of these patients. 
An appropriate method of analysing the published 
accounts of post-therapeutic visual function would be 
to arrange the data according to various irradiation 
modalitis (Table 3). 
The lack of uniformity in the published informa- 
tion prevented the use of one scale in this table, so 
that proper comparisons could not be made and the 
data not added. It would be highly desirable i f the Col- 
laborative Ocular Melanoma Study (COMS) and those 
large centres, which do not participate in the COMS, 
could reach an agreement to use identical designs and 
methods for their future follow-up reports. This would 
enable an appropriate long-term appraisal of the data 
for retention of useful visual function, particularly with 
reference to different treatment modalities. 
It may be noted that some numbers and percentages 
in Table 3 do not correspond with the data provided 
in the original reports. Several authors used percent- 
ages which did not refer to all treated patients, but to 
selected sub-groups. As far as possible, the recalcu- 
lated data in Table 3 refer to all treated patients. The 
information provided confirms that visual acuity has 
decreased to < 6/60 in about 50% of the eyes, three 
years after irradiation using any modality. A continu- 
ing decrease in visual acuity of about 10% per annum 
has also been noted [40]. A randomized study [36] 
to compare the results of helium ion irradiation ver- 
sus I125-brachytherapy showed that visual acuity had 
decreased by _> 4 lines in 69% of each group. Another 
study on visual acuity after II25-therapy [37] revealed 
that 49 (78%) of 63 patients had an acuity decreased 
to <_ 6/30, or an acuity which had decreased 2 lines 
or more. It was concluded that the eye encounters sig- 
nificant morbidity after I125-irradiation. Data on post- 
therapeutic visual acuity after ruthenium 1~ cobalt 6~ 
and proton beam irradiation have either not been pub- 
lished, or have been reported in an incomplete fashion, 
with short follow-up periods, which prevent compari- 
son with other therapeutic modalities. 
After five years, some 70% or more of irradiated 
eyes in which data were verifiable had retained a visual 
acuity of _< 6/60 (Table 3). A case report [41] men- 
tions a maintained reading vision 10 years after proton 
beam irradiation of a histologically proven macular 
melanoma. The generally poor visual result however 
questions the authenticity of the 'fight for sight' jus- 
tification for conservative treatment. The anticipated 
incremental ratio of the 'unfavourable risk' of post- 
therapeutic dissemination from retained viable tumour 
stem cells against the 'benefit' of the conservative pro- 
cedure cannot be assessed before ten post-therapeutic 
years, due to our inability to control metastatic disease. 
The future quality of life after treatment 
There is little consideration i the literature on con- 
servative management of the post-therapeutic physi- 
cal and psychological stresses imposed on the treated 
patients. Considerable anxiety arises from frequent re- 
examination, re-treatment of recurrence, and the treat- 
ment of the complications after irradiation [29, 30, 37, 
42, 43] or intraocular surgery [32]. This contrasts with 
patients treated by primary enucleation, who, more- 
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over, are unaware of the anxious and depressing bur- 
den of harbouring an intraocular malignancy, which 
might continually have the capacity to disseminate and 
to cause a much feared metastatic death. 
By contrast, he impact of enucleation on the post- 
surgical quality of life has not been found to be signif- 
icant in four vision-dependent ac ivities: viz. working; 
driving, reading and television viewing in 62 (87%) of 
71 patients [44]. Fifteen years after enucleation, 18/20 
(90%) of patients retained the ability to drive and 25/26 
(96%) retained the ability to read. Another compara- 
tive study on the same four post-enucleation vision- 
dependent activities as against hose of brachytherapy 
[45] revealed that 48/51 (94%) of the patients after 
enucleation and 46/51 (90%) of those after irradiation 
- mean follow-up of respectively 89 and 87 months 
- reported no vision-related change in any of these 
four activities. It appears questionable, therefore, to 
burden a patient with a normally functioning fellow- 
eye with the incremental risk of preventable metastatic 
death by post-therapeutic d ssemination from a uveal 
melanoma. 
An examplary 25-35 year follow-up report [46] on 
302 between 1943-1952 primary enucleated patients 
with a posterior uveal melanoma, with a follow-up 
percentage of99.8%, revealed that 148 (49%) patients 
had been saved from metastatic death. In the inter- 
vening decades the figure of 40% should, in theo- 
ry, have been markedly improved. Present diagnos- 
tic techniques provide earlier detection rates in small 
melanomas and survival rates after enucleation depend 
largely on the volume of the tumour at the time of 
enucleation. Knowledge that a malignancy has been 
removed completely is the predominant factor in the 
future psychological well being of many patients. 
References  
1. Manschot WA, Van Peperzeel HA. Choroidal melanoma. Enu- 
cleation or observation? A new approach. Arch Ophthalmol 
1980; 98: 71-7. 
2. ManschotWA, van Strik R. Is irradiation a justifiable treatment 
of choroidal melanoma? Analysis of published results. Br J 
Ophthalmol 1987; 71:348-52. 
3. Manschot WA, van Strik R. Uveal melanoma: therapeutic con- 
sequences of doubling times and irradiation results: a review. 
Int Ophthalmo11992; 16: 91-9. 
4. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. 
A review of mortality from choroidal melanoma. II A meta- 
analysis of 5-year mortality rates following enucleation, 1966 
through 1988. Arch Ophthalmol 1992; 110: 245-50. 
5. Markowitz JA, Hawkins BS, Diener-West M, Schachat AP. A 
review of mortality from choroidal melanoma. I. Quality of 
208 
published reports, 1966 through 1988. Arch Ophthalmo11992; 
110: 239-44. 
6. Char DH. Therapeutic options in uveal melanoma. Am J Oph- 
thalmol 1984; 98: 796-9. 
7. Manschot WA. Therapeutic options in uveal melanoma. Cor- 
respondence. Am J Ophthalmol 1985; 99: 615-6. 
8. Davidorf FH, Lang JR. The natural history of malignant 
melanoma of the choroid: small vs large tumors. Trans Am 
Acad Ophthalmol and Otolaryngol 1975; 79:310-20. 
9. Thomas JV, Green R, Manmenee AE. Small choroidal 
melanomas. A long term follow-up study. Arch Ophthalmol 
1979; 97: 861-4. 
10. Barr CC, Sipperly JO, Nicholson DH. Small melanomas ofthe 
choroid. Arch Ophthalmol 1978; 96: 1580-2. 
11. Friberg TR, Fineberg E, McQuaig S. Extremely rapid growth of 
a primary choroidal melanoma. Arch Ophthalmol 1983; 101: 
1375-7. 
12. Angsburger JJ, Gonder JR, Amsel J, Shields JA, Donoso LA. 
Growth rates arid doubling times of posterior uveal melanomas. 
Ophthalmology 1984; 91: 1709-15. 
13. Gass JDM. Comparison of uveal melanoma growth rates with 
mitotic index and mortality. Arch Ophthalmo11985; 103: 924- 
31. 
14. Sahel JA, Pesavento R, Frederick AR, Albert DM. Melanoma 
arising de novo over a 16 month period. Arch Ophthalmol 
1988; 106: 381-5. 
15. Collins VP, Loeffler RK, Tivey H. Observations on growth 
rates of human tumors. Am J Radiol 1956; 76: 988-1000. 
16. Crowley NJ, Seigler HE Late recurrence of malignant 
melanoma. Analysis of 168 patients. Ann Surg 1990; 212: 
173-7. 
17. Augsburger JJ, Gamel JW, Lauritzen K, Brady LW. Cobalt- 
60 plaque radio-therapy vs enucleation for posterior uveal 
melanoma. Am J Opthalmol 1990; 109: 585-92. 
18. Char DH, Quivey JH, Castro JR, Kroll S, Phillips T. Helium 
ions versus iodine-125 brachytherapy in the management of 
uveal melanoma. Ophthalmology 1990; 100: 1547-54. 
19. Seddon JM, Gragoudas ES, Egan KM, Glynn RJ, Fante HS, 
Albert DM. Relative survival rates after alternative therapies 
for uveal melanoma. Ophthalmology 1990; 97: 769-77. 
20. Gragoudas ES, Seddon JM, Egan K. Proton beam irradiation 
of intraocular melanomas. Results in 10 years after treatment. 
Meeting Club Jules Gonin, Vienna, Austria, 1992; Sept 6-10: 
9. 
21. GuthoffR, Frischmuth J, Jensen OA, Bjerrum K, Prause JU. 
Das Aderhautmelanom. Eine retrospektive randomisierte V r- 
gleichsstudie Ruthenium Bestrahlung vs Enukleation. Klin 
Mbl Augenheilk 1992; 200:257-61. 
22. Augsburger JJ, Vrabec TR. Impact of delayed treatment in
growing posterior uveal melanomas. Arch Ophthalmol 1993; 
111: 1382-6. 
23. Tjho-Heslinga RE, Kakebeeke-Kemme HM, Davelaa J, de 
Vrome H, Bleeker JC et al. Results of ruthenium irradiation of 
uveal melanoma. Radiother Oneol 1993; 29: 33-8. 
24. Messmer EP, Bornfeld N, Foerster M, Schilling H, Wessing 
A. Histopathologic findings in eyes treated with a ruthenium 
plaque for uveal melanoma. Graefe's Arch Clin Exp Ophthal- 
mol 1992; 230: 391-6. 
25. Schilling H, Bornfeld N, Friedrichs W, Pauleikhoff D, Saner- 
wein W, Wessing A. Histopathologie findings in large uveal 
melanomas fter brachytherapy with iodine 125 plaques. Ger- 
man J Ophthalmol 1994; 3: 232-8. 
26. Shields CL, Shields JA, Karlson U, Menduke H, Brady LW. 
Enucleation after plaque radiotherapy for posterior uveal 
melanoma. Histopathologic findings. Ophthalmology 1990; 
97: 1665-9. 
27. Klaus H, Lommatzsch PK, Fuchs U. Histopathology studies in 
human malignant melanomas ofthe choroid after unsuccessful 
treatment with l~176 ophthalmic applicators. Graefe's 
Arch Clin Exp Ophthalmol 1991; 229: 480-6. 
28. Saornil MA, Egan KM, Gragoudas ES, Seddon JM, Qualsh 
SM, Albert DM. Histopathology of proton beam-irradiated vs 
enucleated uveal melanomas. Arch Ophthalmol 1992; 110: 
1112-8. 
29. Kincaid MC, Folberg R, Torczinsky E, Zakov ZN, Shore JW et 
al. Complications after proton beam therapy for uveal malig- 
nant melanoma. Ophthalmology 1988; 95: 982-91. 
30. Liszauer AD, Brownstein S,Corriveau C, Deschenes J. A clin- 
icopathological study of seven globes enucleated after primary 
radiation therapy for malignant melanoma of the choroid Or 
ciliary body. Can J Ophthalmo11990; 25:340-4. 
31. Petrovich Z, McDonnell JM, Palmer D, Langholz BM, Liggett 
PE. Histopathologic changes following irradiation for uveal 
tract melanoma. Am J Clin Oncol 1994; 17: 298-306. 
32. Damato BE, Paul J, Foulds WS. Predictive factors of visual 
outcome after local resection of choroidal melanoma. Br J 
Ophthalmol 1993; 77: 616-23. 
33. Lommatzsch PK. Results after/3-irradiation (l~176 of 
choroidal melanomas: 20 years' experience. Br J Ophthalmol 
1986; 70: 844-51. 
34. Linstadt D, Char DH, Castro JR, Phillips TL, Quivey JM, 
Reimers Met al. Vision following helium ion radiotherapy of 
uveal melanomas: a Northern California oncology group study. 
Int J Rad Oncol Biol Phys 1988; 15: 347-52. 
35. Kindy-Degnan NA, Char DH, Castro JR, Kroll S, Stone RD, 
Quivey JM, Reimers Met al. Effects of various doses of radia- 
tion for uveal melanoma on regression, visual acuity, compli- 
cations and survival, Am J Ophthalmol 1989; 107:114-22. 
36. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium 
ions vs iodine 125 brachytherapy in the management of uveal 
melanoma. Ophthalmology 1993; 100: 1547-54. 
37. Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT. Long- 
term results of iodine 125 irradiation of uveal melanoma. Oph- 
thalmology 1992; 99: 767-74. 
38. Fontanesi J, Meyer D, Xu S, Tai D. Treatment of choroidal 
melanoma with I-125 plaque. Int J Rad Oncol Biol Phys 1993; 
26: 619-23. 
39. Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, 
Gragoudas ES. Radiation maculopathy after proton beam irra- 
diation for choroidal melanoma. Ophthalmology 1992; 99: 
1278-85. 
40. Brady LW, Markoe AM, Amendola BE, Karlsson UL, Micaily 
B, Shields JA, Augsburger JJ. The treatment ofprimary ocular 
malignancy. Int J Rad Oncol Biol Phys 1988; 15: 1355-61. 
41. Young LHY, Gragoudas ES. Macular uveal melanoma treated 
with proton beam irradiation: 10-year follow-up observation 
with histopathologic correlation. Retina 1994; 14: 43-6. 
42. Meccham WJ, Char DH, Kroll S, Castro JR, Blakeley EA. 
Anterior segment complications after helium ion radiation ther- 
apy for uveal melanoma: radiation cataract. Arch Ophthalmol 
1994; 112: 197-203. 
43. Gragoudas ES, Egan KH, Walsh SM, Regan S, Munzenrider 
JE, Taratuta V. Lens changes after proton beam irradiation for 
uveal melanoma. Am J Ophthalmo11995; 119: 157-64. 
44. Edwards MG, Schachat AR. Impact of enucleation for 
choroidal melanoma on the performance of vision-dependent 
activities. Arch Ophthalmol 1991; 109: 519-21. 
45. Augsburger JJ, Goel SD. Visual function following enucleation 
or episcleral plaque radiotherapy for posterior uveal melanoma. 
Arch Ophthalmo11994; 112: 786-8. 
46. Jensen OA. Malignant melanomas ofthe human uvea: 25-year 
follow-up of cases in Denmark, 1943-1952. Arch Ophthalmol 
1982; 60: 161-82. 
209 
Address for correspondence: W.A. Manschot, Institute of Pathology, 
Erasmus University, P.O. Box 1738, 3000 DR Rotterdam, 
The Netherlands 
